-
1
-
-
73949087586
-
Personalized cancer therapy with selective kinase inhibitors: An emerging paradigm in medical oncology
-
U. McDermott, and J. Settleman Personalized cancer therapy with selective kinase inhibitors: an emerging paradigm in medical oncology J. Clin. Oncol. 27 2009 5650 5659
-
(2009)
J. Clin. Oncol.
, vol.27
, pp. 5650-5659
-
-
McDermott, U.1
Settleman, J.2
-
2
-
-
0037025173
-
Addiction to oncogenes - The Achilles heal of cancer
-
I.B. Weinstein Addiction to oncogenes - the Achilles heal of cancer Science 297 2005 63 64
-
(2005)
Science
, vol.297
, pp. 63-64
-
-
Weinstein, I.B.1
-
3
-
-
84871721867
-
Overcoming acquired resistance to kinase inhibition: The case of EGFR, ALK, and BRAF
-
S. Giroux Overcoming acquired resistance to kinase inhibition: the case of EGFR, ALK, and BRAF Bioorg. Med. Chem. Lett. 23 2013 394 401
-
(2013)
Bioorg. Med. Chem. Lett.
, vol.23
, pp. 394-401
-
-
Giroux, S.1
-
4
-
-
84858005733
-
Acquired resistance to drugs targeting receptor tyrosine kinases
-
S.A. Rosenzweig Acquired resistance to drugs targeting receptor tyrosine kinases Biochem. Pharmacol. 83 2012 1041 1048
-
(2012)
Biochem. Pharmacol.
, vol.83
, pp. 1041-1048
-
-
Rosenzweig, S.A.1
-
5
-
-
84871698293
-
Drug conjugates such as antibody drug conjugates (ADCs), immuotoxins and immunoliposomes challenge daily clinical practice
-
W.-D. Janthur et al. Drug conjugates such as antibody drug conjugates (ADCs), immuotoxins and immunoliposomes challenge daily clinical practice Int. J. Mol. Sci. 13 2012 16020 16045
-
(2012)
Int. J. Mol. Sci.
, vol.13
, pp. 16020-16045
-
-
Janthur, W.-D.1
-
6
-
-
80054092984
-
Antibody-radionuclide conjugates for cancer therapy: Historical considerations and new trends
-
M. Steiner, and D. Neri Antibody-radionuclide conjugates for cancer therapy: historical considerations and new trends Clin. Cancer Res. 17 2011 6406 6416
-
(2011)
Clin. Cancer Res.
, vol.17
, pp. 6406-6416
-
-
Steiner, M.1
Neri, D.2
-
7
-
-
0343122931
-
The relationship existing between chemical constitution, distribution and pharmacological action
-
Wiley & Sons
-
P. Ehrlich The relationship existing between chemical constitution, distribution and pharmacological action Collected Studies on Immunity 1906 Wiley & Sons 441 450
-
(1906)
Collected Studies on Immunity
, pp. 441-450
-
-
Ehrlich, P.1
-
8
-
-
84903754700
-
Chemotherapy. Proceedings of 17th international congress of medicine
-
F. Himmelwiet, Pergamon Press
-
P. Ehrlich Chemotherapy. Proceedings of 17th international congress of medicine F. Himmelwiet, Collected Papers of Paul Ehrlich 1913 Pergamon Press 505 518
-
(1913)
Collected Papers of Paul Ehrlich
, pp. 505-518
-
-
Ehrlich, P.1
-
9
-
-
84961023030
-
Effet sur la leucemie L1210 de la souris d'une combinaison par diazotation d'A-methopterine et de gamma-globulines de hamsters porteur de cette leucemie par heterogreffe
-
G. Mathé et al. Effet sur la leucemie L1210 de la souris d'une combinaison par diazotation d'A-methopterine et de gamma-globulines de hamsters porteur de cette leucemie par heterogreffe C. R. Acad. Sci. 246 1958 1626 1628
-
(1958)
C. R. Acad. Sci.
, vol.246
, pp. 1626-1628
-
-
Mathé, G.1
-
10
-
-
0014202195
-
Immunoradioactive agent against cancer
-
T. Ghose et al. Immunoradioactive agent against cancer Br. Med. J. 1 1967 90 93
-
(1967)
Br. Med. J.
, vol.1
, pp. 90-93
-
-
Ghose, T.1
-
11
-
-
0015333917
-
Antibody as carrier of chlorambucil
-
T. Ghose et al. Antibody as carrier of chlorambucil Cancer 29 1972 1398 1400
-
(1972)
Cancer
, vol.29
, pp. 1398-1400
-
-
Ghose, T.1
-
12
-
-
0016831976
-
Suppression of tumor growth in mice by a drug-antibody conjugate using a novel approach to linkage
-
G.F. Rowland et al. Suppression of tumor growth in mice by a drug-antibody conjugate using a novel approach to linkage Nature 255 1975 487 488
-
(1975)
Nature
, vol.255
, pp. 487-488
-
-
Rowland, G.F.1
-
13
-
-
0016756272
-
Continuous cultures of fused cells secreting antibody of predefined specificity
-
G. Kohler, and C. Milstein Continuous cultures of fused cells secreting antibody of predefined specificity Nature 256 1975 495 497
-
(1975)
Nature
, vol.256
, pp. 495-497
-
-
Kohler, G.1
Milstein, C.2
-
14
-
-
0020674198
-
Localisation and toxicity study of a vindesine-anti-CEA conjugate in patients with advanced cancer
-
C.H.J. Ford et al. Localization and toxicity study of a vindesine-anti-CEA conjugate in patients with advanced cancer Br. J. Cancer 47 1983 35 42 (Pubitemid 13176227)
-
(1983)
British Journal of Cancer
, vol.47
, Issue.1
, pp. 35-42
-
-
Ford, C.H.J.1
Newman, C.E.2
Johnson, J.R.3
-
15
-
-
0023911111
-
Reshaping human antibodies for therapy
-
L. Riechmann et al. Reshaping human antibodies for therapy Nature 332 1988 323 332
-
(1988)
Nature
, vol.332
, pp. 323-332
-
-
Riechmann, L.1
-
16
-
-
0028067743
-
Antibody-targeted drugs for the therapy of cancer
-
G.A. Pietersz, and K. Krauer Antibody-targeted drugs for the therapy of cancer J. Drug Targeting 2 1994 183 215 (Pubitemid 24310624)
-
(1994)
Journal of Drug Targeting
, vol.2
, Issue.3
, pp. 183-215
-
-
Pietersz, G.A.1
Krauer, K.2
-
17
-
-
0025854110
-
The human immune response to KS1/4-desacetylvinblastine (LY256787) and KS1/4-desacetylvinblastine hydrazide (LY203728) in single and multiple dose clinical studies
-
B.H. Petersen et al. The human immune response to KS1/4- desacetylvinblastine (LY256787) and KS1/4-desacetylvinblastine hydrazide (LY203728) in single and multiple dose clinical studies Cancer Res. 51 1991 2286 2290
-
(1991)
Cancer Res.
, vol.51
, pp. 2286-2290
-
-
Petersen, B.H.1
-
18
-
-
0027218284
-
Cure of xenografted human carcinomas by BR96-doxorubicin immunoconjugates
-
P.A. Trail et al. Cure of xenografted human carcinomas by BR96-doxorubicin immunoconjugates Science 261 1993 212 215 (Pubitemid 23265398)
-
(1993)
Science
, vol.261
, Issue.5118
, pp. 212-215
-
-
Trail, P.A.1
Willner, D.2
Lasch, S.J.3
Henderson, A.J.4
Hofstead, S.5
Casazza, A.M.6
Firestone, R.A.7
Hellstrom, I.8
Hellstrom, K.E.9
-
19
-
-
67649886201
-
Potent antibody drug conjugates for cancer therapy
-
P.D. Senter Potent antibody drug conjugates for cancer therapy Curr. Opin. Chem. Biol. 13 2009 235 244
-
(2009)
Curr. Opin. Chem. Biol.
, vol.13
, pp. 235-244
-
-
Senter, P.D.1
-
20
-
-
0035397980
-
Efficacy and safety of gemtuzumab ozogamicin in patients with CD33-positive acute myeloid leukemia in first relapse
-
E.L. Sievers et al. Efficacy and safety of Mylotarg (gemtuzumab ozogamicin) with CD33-postive acute myeloid leukemia in first relapse J. Clin. Oncol. 19 2001 3244 3254 (Pubitemid 32591442)
-
(2001)
Journal of Clinical Oncology
, vol.19
, Issue.13
, pp. 3244-3254
-
-
Sievers, E.L.1
Larson, R.A.2
Stadtmauer, E.A.3
Estey, E.4
Lowenberg, B.5
Dombret, H.6
Karanes, C.7
Theobald, M.8
Bennett, J.M.9
Sherman, M.L.10
Berger, M.S.11
Eten, C.B.12
Loken, M.R.13
Van Dongen, J.J.M.14
Bernstein, I.D.15
Appelbaum, F.R.16
-
21
-
-
0035883042
-
Multidrug-resistance phenotype and clinical responses to gemtuzumab ozogamicin
-
M.L. Linenberger et al. Multidrug-resistance phenotype and clinical responses to gemtuzumab ozogamicin Blood 98 2001 988 994
-
(2001)
Blood
, vol.98
, pp. 988-994
-
-
Linenberger, M.L.1
-
22
-
-
78049515807
-
Brentuximab vedotin (SGN-35) for relapsed CD30-positive lymphomas
-
A. Younes et al. Brentuximab vedotin (SGN-35) for relapsed CD30-positive lymphomas N. Engl. J. Med. 363 2010 1812 1821
-
(2010)
N. Engl. J. Med.
, vol.363
, pp. 1812-1821
-
-
Younes, A.1
-
23
-
-
84863688504
-
The discovery and development of brentuximab vedotin for use in relapsed Hodgkin lymphoma and systemic anaplastic large cell lymphoma
-
P. Senter, and E.L. Sievers The discovery and development of brentuximab vedotin for use in relapsed Hodgkin lymphoma and systemic anaplastic large cell lymphoma Nat. Biotechnol. 30 2012 631 637
-
(2012)
Nat. Biotechnol.
, vol.30
, pp. 631-637
-
-
Senter, P.1
Sievers, E.L.2
-
24
-
-
80054092983
-
Trastuzumab emtansine: A unique antibody-drug conjugate in development for human epidermal growth factor receptor 2-positive cancer
-
P.M. LoRusso et al. Trastuzumab emtansine: a unique antibody-drug conjugate in development for human epidermal growth factor receptor 2-positive cancer Clin. Cancer Res. 17 2011 6437 6447
-
(2011)
Clin. Cancer Res.
, vol.17
, pp. 6437-6447
-
-
Lorusso, P.M.1
-
25
-
-
84868520609
-
Trastuzumab emtansine for HER2-positive advanced breast cancer
-
S. Verma et al. Trastuzumab emtansine for HER2-positive advanced breast cancer N. Engl. J. Med. 367 2012 1783 1791
-
(2012)
N. Engl. J. Med.
, vol.367
, pp. 1783-1791
-
-
Verma, S.1
-
26
-
-
84877310777
-
Maturing antibody-drug conjugate pipeline hits 30
-
A. Mullard Maturing antibody-drug conjugate pipeline hits 30 Nat. Rev. Drug Discov. 12 2013 329 332
-
(2013)
Nat. Rev. Drug Discov.
, vol.12
, pp. 329-332
-
-
Mullard, A.1
-
27
-
-
84873053339
-
Antibody-drug conjugates in cancer therapy
-
E.L. Sievers, and P.D. Senter Antibody-drug conjugates in cancer therapy Annu. Rev. Med. 64 2013 15 29
-
(2013)
Annu. Rev. Med.
, vol.64
, pp. 15-29
-
-
Sievers, E.L.1
Senter, P.D.2
-
28
-
-
84872846418
-
Implications of receptor-mediated endocytosis and intracellular trafficking dynamics in the development of antibody drug conjugates
-
M. Ritchie et al. Implications of receptor-mediated endocytosis and intracellular trafficking dynamics in the development of antibody drug conjugates mAbs 5 2013 13 21
-
(2013)
MAbs
, vol.5
, pp. 13-21
-
-
Ritchie, M.1
-
29
-
-
0025359146
-
Expression of the HER-2/neu proto-oncogene in normal human adult and fetal tissues
-
M.F. Press et al. Expression of the HER-2/neu proto-oncogene in normal human adult and fetal tissues Oncogene 5 1990 953 962
-
(1990)
Oncogene
, vol.5
, pp. 953-962
-
-
Press, M.F.1
-
31
-
-
33745912498
-
Safety of rituximab maintenance therapy in follicular lymphomas
-
P. Solal-Celigny Safety of rituximab maintenance therapy in follicular lymphomas Leuk. Res. 30S1 2006 S16 S21
-
(2006)
Leuk. Res.
, vol.30 S1
-
-
Solal-Celigny, P.1
-
32
-
-
9444260479
-
Biological impediments to monoclonal antibody-based cancer immunotherapy
-
J. Christiansen, and A.K. Rajasekaran Biological impediments to monoclonal antibody-based cancer immunotherapy Mol. Cancer Ther. 3 2004 1493 1501 (Pubitemid 39562594)
-
(2004)
Molecular Cancer Therapeutics
, vol.3
, Issue.11
, pp. 1493-1501
-
-
Christiansen, J.1
Rajasekaran, A.K.2
-
33
-
-
33644787435
-
Antibody-drug conjugates designed to eradicate tumors with homogeneous and heterogeneous expression of the target antigen
-
Y.V. Kovtun et al. Antibody-drug conjugates designed to eradicate tumors with homogeneous and heterogeneous expression of the target antigen Cancer Res. 66 2006 3214 3221
-
(2006)
Cancer Res.
, vol.66
, pp. 3214-3221
-
-
Kovtun, Y.V.1
-
34
-
-
78650286160
-
Investigational antibody-drug conjugates for hematological malignancies
-
A.G. Polson et al. Investigational antibody-drug conjugates for hematological malignancies Expert Opin. Investig. Drugs 20 2011 75 85
-
(2011)
Expert Opin. Investig. Drugs
, vol.20
, pp. 75-85
-
-
Polson, A.G.1
-
35
-
-
84877256857
-
Insights into antibody-drug conjugates: Bioanalysis and biomeasures in discovery
-
T. Clark et al. Insights into antibody-drug conjugates: bioanalysis and biomeasures in discovery Bioanalysis 5 2013 985 987
-
(2013)
Bioanalysis
, vol.5
, pp. 985-987
-
-
Clark, T.1
-
36
-
-
70350494468
-
Therapeutic potential of an anti-CD79b antibody-drug conjugate, anti-CD79b-vc-MMAE, for the treatment of non-Hodgkin lymphoma
-
D. Dornan et al. Therapeutic potential of an anti-CD79b antibody-drug conjugate, anti-CD79b-vc-MMAE, for the treatment of non-Hodgkin lymphoma Blood 114 2009 2721 2729
-
(2009)
Blood
, vol.114
, pp. 2721-2729
-
-
Dornan, D.1
-
37
-
-
33746095034
-
Potent cytotoxicity of an auristatin-containing antibody-drug conjugate targeting melanoma cells expressing melanotransferrin/p97
-
DOI 10.1158/1535-7163.MCT-06-0026
-
L.M. Smith et al. Potent cytotoxicity of an auristatin-containing antibody-drug conjugate targeting melanoma cells expressing melanotransferrin/ p97 Mol. Cancer Ther. 5 2006 1474 1482 (Pubitemid 44070484)
-
(2006)
Molecular Cancer Therapeutics
, vol.5
, Issue.6
, pp. 1474-1482
-
-
Smith, L.M.1
Nesterova, A.2
Alley, S.C.3
Torgov, M.Y.4
Carter, P.J.5
-
39
-
-
84886825064
-
SGN-CD33A: A novel CD33-targeting antibody-drug conjugate utilizing a pyrrolobenzodiazepine dimer is active in models of drug-resistant AML
-
M.S.K. Sutherland et al. SGN-CD33A: a novel CD33-targeting antibody-drug conjugate utilizing a pyrrolobenzodiazepine dimer is active in models of drug-resistant AML Blood 122 2013 1455 1463
-
(2013)
Blood
, vol.122
, pp. 1455-1463
-
-
Sutherland, M.S.K.1
-
40
-
-
80052740269
-
In vitro and in vivo responses of advanced prostate tumors to PSMA ADC, an auristatin-conjugated antibody to prostate-specific membrane antigen
-
X. Wang et al. In vitro and in vivo responses of advanced prostate tumors to PSMA ADC, an auristatin-conjugated antibody to prostate-specific membrane antigen Mol. Cancer Ther. 10 2011 1728 1739
-
(2011)
Mol. Cancer Ther.
, vol.10
, pp. 1728-1739
-
-
Wang, X.1
-
41
-
-
79952256064
-
An antibody-drug conjugate targeting the endothelin B receptor for the treatment of melanoma
-
J. Asudi et al. An antibody-drug conjugate targeting the endothelin B receptor for the treatment of melanoma Clin. Cancer Res. 17 2011 965 975
-
(2011)
Clin. Cancer Res.
, vol.17
, pp. 965-975
-
-
Asudi, J.1
-
42
-
-
84878263190
-
Robo4 is an effective tumor endothelial marker for antibody-drug conjugates based on the rapid isolation of the anti-Robo4 cell-internalizing antibody
-
M. Yoshikawa et al. Robo4 is an effective tumor endothelial marker for antibody-drug conjugates based on the rapid isolation of the anti-Robo4 cell-internalizing antibody Blood 121 2013 2804 2813
-
(2013)
Blood
, vol.121
, pp. 2804-2813
-
-
Yoshikawa, M.1
-
43
-
-
51049105989
-
Effect of antigen turnover rate and expression level on antibody penetration into tumor spheroids
-
M.E. Ackerman et al. Effect of antigen turnover rate and expression level on antibody penetration into tumor spheroids Mol. Cancer Ther. 7 2008 2233 2240
-
(2008)
Mol. Cancer Ther.
, vol.7
, pp. 2233-2240
-
-
Ackerman, M.E.1
-
44
-
-
33646352962
-
Potent antibody therapeutics by design
-
P. Carter Potent antibody therapeutics by design Nat. Rev. Immunol. 6 2006 343 357
-
(2006)
Nat. Rev. Immunol.
, vol.6
, pp. 343-357
-
-
Carter, P.1
-
45
-
-
84887068994
-
Targeting HER21 breast cancer cells: Lysosomal accumulation of anti-HER2 antibodies is influenced by antibody binding site and conjugation to polymeric nanoparticles
-
S.C. Owen et al. Targeting HER21 breast cancer cells: lysosomal accumulation of anti-HER2 antibodies is influenced by antibody binding site and conjugation to polymeric nanoparticles J. Control. Release 172 2013 395 404
-
(2013)
J. Control. Release
, vol.172
, pp. 395-404
-
-
Owen, S.C.1
-
46
-
-
33744537358
-
Lysosomal trafficking and cysteine protease metabolism confer target-specific cytotoxicity by peptide-linked anti-CD30-auristatin conjugates
-
M.S.K. Sutherland et al. Lysosomal trafficking and cysteine protease metabolism confer target-specific cytotoxicity by peptide-linked anti-CD30-auristatin conjugates J. Biol. Chem. 281 2006 10540 10547
-
(2006)
J. Biol. Chem.
, vol.281
, pp. 10540-10547
-
-
Sutherland, M.S.K.1
-
47
-
-
15244352751
-
A calicheamicin conjugate with a fully humanized anti-MUC1 antibody shows potent antitumor effects in breast and ovarian tumor xenografts
-
DOI 10.1021/bc049794n
-
P.R. Hamann et al. A calicheamicin conjugate with a fully humanized anti-MUC1 antibody shows potent antitumor effects in breast and ovarian tumor xenografts Bioconjug. Chem. 16 2005 354 360 (Pubitemid 40388211)
-
(2005)
Bioconjugate Chemistry
, vol.16
, Issue.2
, pp. 354-360
-
-
Hamann, P.R.1
Hinman, L.M.2
Beyer, C.F.3
Lindh, D.4
Upeslacis, J.5
Shochat, D.6
Mountain, A.7
-
48
-
-
9744243565
-
Efficient elimination of B-lineage lymphomas by anti-CD20-auristatin conjugates
-
C.L. Law et al. Efficient elimination of B-lineage lymphomas by anti-CD20-auristatin conjugates Clin. Cancer Res. 10 2004 7842 7851
-
(2004)
Clin. Cancer Res.
, vol.10
, pp. 7842-7851
-
-
Law, C.L.1
-
49
-
-
52549121490
-
Kinetics of anti-carcinoembryonic antigen antibody internalization: Effects of affinity, bivalency, and stability
-
M.M. Schmidt et al. Kinetics of anti-carcinoembryonic antigen antibody internalization: effects of affinity, bivalency, and stability Cancer Immunol. Immunother. 57 2008 1879 1890
-
(2008)
Cancer Immunol. Immunother.
, vol.57
, pp. 1879-1890
-
-
Schmidt, M.M.1
-
50
-
-
0037931402
-
Quantitative analysis of HER2-mediated effects on HER2 and epidermal growth factor receptor endocytosis. Distribution of homo- and heterodimers depends on relative HER2 levels
-
DOI 10.1074/jbc.M300477200
-
B.S. Hendriks et al. Quantitative analysis of HER2-mediated effects on HER2 and epidermal growth factor receptor endocytosis: distribution of homo- and heterodimers depends on relative HER2 levels J. Biol. Chem. 278 2003 23343 23351 (Pubitemid 36830149)
-
(2003)
Journal of Biological Chemistry
, vol.278
, Issue.26
, pp. 23343-23351
-
-
Hendriks, B.S.1
Opresko, L.K.2
Wiley, H.S.3
Lauffenburger, D.4
-
51
-
-
0029820796
-
Internalization and catabolism of radiolabelled antibodies to the MHC class-II invariant chain by B-cell lymphomas
-
H.J. Hansen et al. Internalization and catabolism of radiolabelled antibodies to the MHC class-II invariant chain by B-cell lymphomas Biochem. J. 320 1996 293 300
-
(1996)
Biochem. J.
, vol.320
, pp. 293-300
-
-
Hansen, H.J.1
-
52
-
-
22344432668
-
Anti-CD74 antibody-doxorubicin conjugate, IMMU-110, in a human multiple myeloma xenograft and in monkeys
-
DOI 10.1158/1078-0432.CCR-05-0204
-
P. Sapra et al. Anti-CD74 antibody-doxorubicin conjugate, IMMU-110, in a human multiple myeloma xenograft and in monkeys Clin. Cancer Res. 11 2005 5257 5264 (Pubitemid 41003714)
-
(2005)
Clinical Cancer Research
, vol.11
, Issue.14
, pp. 5257-5264
-
-
Sapra, P.1
Stein, R.2
Pickett, J.3
Qu, Z.4
Govindan, S.V.5
Cardillo, T.M.6
Hansen, H.J.7
Horak, I.D.8
Griffiths, G.L.9
Goldenberg, D.M.10
-
53
-
-
20344367537
-
Tumour vascular targeting
-
DOI 10.1038/nrc1627
-
D. Neri, and R. Bicknell Tumour vascular targeting Nat. Rev. Cancer 5 2005 436 446 (Pubitemid 40791486)
-
(2005)
Nature Reviews Cancer
, vol.5
, Issue.6
, pp. 436-446
-
-
Neri, D.1
Bicknell, R.2
-
54
-
-
79953185350
-
A chemically modified antibody mediates complete eradication of tumours by selective disruption of tumour blood vessels
-
A. Palumbo et al. A chemically modified antibody mediates complete eradication of tumours by selective disruption of tumour blood vessels Br. J. Cancer 104 2011 1106 1115
-
(2011)
Br. J. Cancer
, vol.104
, pp. 1106-1115
-
-
Palumbo, A.1
-
55
-
-
54049093284
-
Engineered anti-CD70 antibody-drug conjugate with increased therapeutic index
-
C.F. McDonagh et al. Engineered anti-CD70 antibody-drug conjugate with increased therapeutic index Mol. Cancer Ther. 7 2008 2913 2923
-
(2008)
Mol. Cancer Ther.
, vol.7
, pp. 2913-2923
-
-
McDonagh, C.F.1
-
56
-
-
79959700509
-
Trastuzumab-DM1 (T-DM1) retains all the mechanisms of action of trastuzumab and efficiently inhibits growth of lapatinib insensitive breast cancer
-
T.T. Junttila et al. Trastuzumab-DM1 (T-DM1) retains all the mechanisms of action of trastuzumab and efficiently inhibits growth of lapatinib insensitive breast cancer Breast Cancer Res. Treat. 128 2011 347 356
-
(2011)
Breast Cancer Res. Treat.
, vol.128
, pp. 347-356
-
-
Junttila, T.T.1
-
58
-
-
31544455876
-
Antitumor efficacy of a combination of CMC-544 (inotuzumab ozogamicin), a CD22-targeted cytotoxic immunoconjugate of calicheamicin, and rituximab against non-Hodgkin's B-cell lymphoma
-
J.F. DiJoseph et al. Antitumor efficacy of a combination of CMC-544 (inotuzumab ozogamicin), a CD22-targeted cytotoxic immunoconjugate of calicheamicin, and rituximab against non-Hodgkin's B-cell lymphoma Clin. Cancer Res. 12 2006 242 249
-
(2006)
Clin. Cancer Res.
, vol.12
, pp. 242-249
-
-
Dijoseph, J.F.1
-
59
-
-
79952660539
-
Antibody-drug conjugates: Using monoclonal antibodies for delivery of cytotoxic payloads to cancer cells
-
V.S. Goldmacher, and Y.V. Kovtun Antibody-drug conjugates: using monoclonal antibodies for delivery of cytotoxic payloads to cancer cells Ther. Deliv. 2 2011 397 416
-
(2011)
Ther. Deliv.
, vol.2
, pp. 397-416
-
-
Goldmacher, V.S.1
Kovtun, Y.V.2
-
60
-
-
48649094750
-
Fully human antibodies from transgenic mouse and phage display platforms
-
N. Lonberg Fully human antibodies from transgenic mouse and phage display platforms Curr. Opin. Immunol. 20 2008 450 459
-
(2008)
Curr. Opin. Immunol.
, vol.20
, pp. 450-459
-
-
Lonberg, N.1
-
61
-
-
41049106764
-
Determination of pharmacokinetic values of calicheamicin-antibody conjugates in mice by plasmon resonance analysis of small (5 μl) blood samples
-
DOI 10.1007/s00280-007-0560-2
-
E.R. Boghaert et al. Determination of pharmacokinetic values of calicheamicin-antibody conjugates in mice by plasmon resonance analysis of small (5 micron) blood samples Cancer Chemother. Pharmacol. 61 2008 1027 1035 (Pubitemid 351423131)
-
(2008)
Cancer Chemotherapy and Pharmacology
, vol.61
, Issue.6
, pp. 1027-1035
-
-
Boghaert, E.R.1
Khandke, K.M.2
Sridharan, L.3
Dougher, M.4
Dijoseph, J.F.5
Kunz, A.6
Hamann, P.R.7
Moran, J.8
Chaudhary, I.9
Damle, N.K.10
-
62
-
-
0032402354
-
Cathepsin B-sensitive dipeptide prodrugs. 1. A model study of structural requirements for efficient release of doxorubicin
-
PII S0960894X9800609X
-
G.M. Dubowchik, and R.A. Firestone Cathepsin B-sensitive dipeptide prodrugs. 1. A model study of structural requirements for efficient release of doxorubicin Bioorg. Med. Chem. Lett. 8 1998 3341 3346 (Pubitemid 28547069)
-
(1998)
Bioorganic and Medicinal Chemistry Letters
, vol.8
, Issue.23
, pp. 3341-3346
-
-
Dubowchik, G.M.1
Firestone, R.A.2
-
63
-
-
0036074253
-
Cathepsin B-labile dipeptide linkers for lysosomal release of doxorubicin from internalizing immunoconjugates: Model studies of enzymatic drug release and antigen-specific in vitro anticancer activity
-
DOI 10.1021/bc025536j
-
G.M. Dubowchik et al. Cathepsin B-labile dipeptide linkers for lysosomal release of doxorubicin from internalizing immunoconjugates: model studies of enzymatic drug release and antigen-specific in vitro anticancer activity Bioconjug. Chem. 13 2002 855 869 (Pubitemid 34801129)
-
(2002)
Bioconjugate Chemistry
, vol.13
, Issue.4
, pp. 855-869
-
-
Dubowchik, G.M.1
Firestone, R.A.2
Padilla, L.3
Willner, D.4
Hofstead, S.J.5
Mosure, K.6
Knipe, J.O.7
Lasch, S.J.8
Trail, P.A.9
-
64
-
-
10744222473
-
Development of potent monoclonal antibody auristatin conjugates for cancer therapy
-
DOI 10.1038/nbt832
-
S.O. Doronina et al. Development of potent monoclonal antibody auristatin conjugates for cancer therapy Nat. Biotechnol. 21 2003 778 784 (Pubitemid 36791396)
-
(2003)
Nature Biotechnology
, vol.21
, Issue.7
, pp. 778-784
-
-
Doronina, S.O.1
Toki, B.E.2
Torgov, M.Y.3
Mendelsohn, B.A.4
Cerveny, C.G.5
Chace, D.F.6
DeBlanc, R.L.7
Gearing, R.P.8
Bovee, T.D.9
Siegall, C.B.10
Francisco, J.A.11
Wahl, A.F.12
Meyer, D.L.13
Senter, P.D.14
-
65
-
-
74949107560
-
Antibody-drug conjugates: Linking cytotoxic payloads to monoclonal antibodies
-
L. Ducry, and B. Stump Antibody-drug conjugates: linking cytotoxic payloads to monoclonal antibodies Bioconjug. Chem. 21 2010 5 13
-
(2010)
Bioconjug. Chem.
, vol.21
, pp. 5-13
-
-
Ducry, L.1
Stump, B.2
-
66
-
-
0036007596
-
Gemtuzumab ozogamicin, a potent and selective anti-CD33 antibody - Calicheamicin conjugate for treatment of acute myeloid leukemia
-
DOI 10.1021/bc010021y
-
P.R. Hamann et al. Gemtuzumab ozogamicin, a potent and selective anti-CD33 antibody-calicheamicin conjugate for the treatment of acute myeloid leukemia Bioconjug. Chem. 13 2002 47 58 (Pubitemid 34119634)
-
(2002)
Bioconjugate Chemistry
, vol.13
, Issue.1
, pp. 47-58
-
-
Hamann, P.R.1
Hinman, L.M.2
Hollander, I.3
Beyer, C.F.4
Lindh, D.5
Holcomb, R.6
Hallett, W.7
Tsou, H.-R.8
Upeslacis, J.9
Shochat, D.10
Mountain, A.11
Flowers, D.A.12
Bernstein, I.13
-
67
-
-
79960356302
-
Investigational antibody drug conjugates for solid tumors
-
P. Sapra et al. Investigational antibody drug conjugates for solid tumors Expert Opin. Investig. Drugs 20 2011 1131 1149
-
(2011)
Expert Opin. Investig. Drugs
, vol.20
, pp. 1131-1149
-
-
Sapra, P.1
-
68
-
-
0347926091
-
Drug delivery strategy utilizing conjugation via reversible disulfide linkages: Role and site of cellular reducing activities
-
G. Sato et al. Drug delivery strategy utilizing conjugation via reversible disulfide linkages: role and site of cellular reducing activities Adv. Drug Deliv. Rev. 55 2003 199 215
-
(2003)
Adv. Drug Deliv. Rev.
, vol.55
, pp. 199-215
-
-
Sato, G.1
-
69
-
-
74949139946
-
Tumor delivery and in vivo processing of disulfide-linked and thioether-linked antibody-maytansinoid conjugates
-
H.K. Erickson Tumor delivery and in vivo processing of disulfide-linked and thioether-linked antibody-maytansinoid conjugates Bioconjug. Chem. 21 2010 84 92
-
(2010)
Bioconjug. Chem.
, vol.21
, pp. 84-92
-
-
Erickson, H.K.1
-
70
-
-
84903791373
-
-
Inc. Protein-polymer-drug conjugates. U.S. Patent Appl. 20130101546
-
Yurkovetskiy, A.V. Mersana Therapeutics, Inc. Protein-polymer-drug conjugates. U.S. Patent Appl. 20130101546.
-
Mersana Therapeutics
-
-
Yurkovetskiy, A.V.1
-
72
-
-
78650532605
-
The legumain protease-activated auristatin prodrugs suppress tumor growth and metastasis without toxicity
-
K.M. Bajjuri et al. The legumain protease-activated auristatin prodrugs suppress tumor growth and metastasis without toxicity ChemMedChem 6 2011 54 59
-
(2011)
ChemMedChem
, vol.6
, pp. 54-59
-
-
Bajjuri, K.M.1
-
73
-
-
77956498321
-
Expanded utility of the β-glucuronide linker: ADCs that deliver phenolic cytotoxic agents
-
S.C. Jeffrey et al. Expanded utility of the β-glucuronide linker: ADCs that deliver phenolic cytotoxic agents ACS Med. Chem. Lett. 1 2010 277 280
-
(2010)
ACS Med. Chem. Lett.
, vol.1
, pp. 277-280
-
-
Jeffrey, S.C.1
-
74
-
-
84868560034
-
The first generation of β-galactosidase-responsive prodrugs designed for the selective treatment of solid tumors in prodrug monotherapy
-
T. Legigan et al. The first generation of β-galactosidase-responsive prodrugs designed for the selective treatment of solid tumors in prodrug monotherapy Angew. Chem. Int. Ed. 51 2012 11606 11610
-
(2012)
Angew. Chem. Int. Ed.
, vol.51
, pp. 11606-11610
-
-
Legigan, T.1
-
75
-
-
0026593928
-
Immunoconjugates containing novel maytansinoids: Promising anticancer drugs
-
R.V. Chari et al. Immunoconjugates containing novel maytansinoids: promising anticancer drugs Cancer Res. 52 1992 127 131
-
(1992)
Cancer Res.
, vol.52
, pp. 127-131
-
-
Chari, R.V.1
-
76
-
-
0027194197
-
Preparation and characterization of monoclonal antibody conjugates of the calicheamicins: A novel and potent family of antitumor antibiotics
-
L.M. Hinmann et al. Preparation and characterization of monoclonal antibody conjugates of the calicheamicins: a novel and potent family of antitumor antibiotics Cancer Res. 53 1993 3336 3342
-
(1993)
Cancer Res.
, vol.53
, pp. 3336-3342
-
-
Hinmann, L.M.1
-
79
-
-
0032975042
-
Randomized phase II study of BR96-doxorubicin conjugate in patients with metastatic breast cancer
-
A.W. Tolcher et al. Randomized phase II study of BR96-doxorubicin conjugate in patients with metastatic breast cancer J. Clin. Oncol. 17 1999 478 484 (Pubitemid 29075231)
-
(1999)
Journal of Clinical Oncology
, vol.17
, Issue.2
, pp. 478-484
-
-
Tolcher, A.W.1
Sugarman, S.2
Gelmon, K.A.3
Cohen, R.4
Saleh, M.5
Isaacs, C.6
Young, L.7
Healey, D.8
Onetto, N.9
Slichenmyer, W.10
-
80
-
-
80054098573
-
Antibody conjugate therapeutics: Challenges and potential
-
B.A. Teicher, and R.V.J. Chari Antibody conjugate therapeutics: challenges and potential Clin. Cancer Res. 17 2011 6389 6397
-
(2011)
Clin. Cancer Res.
, vol.17
, pp. 6389-6397
-
-
Teicher, B.A.1
Chari, R.V.J.2
-
81
-
-
79955867207
-
The development of pyrrolobenzodiazepines as antitumor agents
-
J.A. Hartley The development of pyrrolobenzodiazepines as antitumor agents Expert Opin. Investig. Drugs 20 2011 733 744
-
(2011)
Expert Opin. Investig. Drugs
, vol.20
, pp. 733-744
-
-
Hartley, J.A.1
-
82
-
-
84860142832
-
Therapeutic potential of amanitin-conjugated anti-epithelial cell adhesion molecule monoclonal antibody against pancreatic carcinoma
-
G. Moldenhauer et al. Therapeutic potential of amanitin-conjugated anti-epithelial cell adhesion molecule monoclonal antibody against pancreatic carcinoma J. Natl. Cancer Inst. 104 2012 1 13
-
(2012)
J. Natl. Cancer Inst.
, vol.104
, pp. 1-13
-
-
Moldenhauer, G.1
-
83
-
-
84943581048
-
-
Igenica, Inc. U.S. Patent Appl. 20130224228
-
Jackson, D.Y. and Edward, H.A. Igenica, Inc. Antibody-drug conjugates and related compounds, compositions, and methods. U.S. Patent Appl. 20130224228.
-
Antibody-drug Conjugates and Related Compounds, Compositions, and Methods
-
-
Jackson, D.Y.1
Edward, H.A.2
-
85
-
-
84969563269
-
-
Medarex, Inc. U.S. Patent 8,394,922 B2
-
Cheng, H. et al. Medarex, Inc. Antiproliferative compounds, conjugates thereof, methods therefor, and uses thereof. U.S. Patent 8,394,922 B2.
-
Antiproliferative Compounds, Conjugates Thereof, Methods Therefor, and Uses Thereof
-
-
Cheng, H.1
-
86
-
-
27744562662
-
MRP3, BCRP, and P-glycoprotein activities are prognostic factors in adult acute myeloid leukemia
-
DOI 10.1158/1078-0432.CCR-04-1895
-
Z. Benderra et al. MRP3, BCRP, and P-glycoprotein activities are prognostic factors in adult acute myeloid leukemia Clin. Cancer Res. 11 2005 7764 7772 (Pubitemid 41611620)
-
(2005)
Clinical Cancer Research
, vol.11
, Issue.21
, pp. 7764-7772
-
-
Benderra, Z.1
Faussat, A.M.2
Sayada, L.3
Perrot, J.-Y.4
Tang, R.5
Chaoui, D.6
Morjani, H.7
Marzac, C.8
Marie, J.-P.9
Legrand, O.10
-
87
-
-
0033852105
-
Calicheamicin-conjugated humanized anti-CD33 monoclonal antibody (gemtuzumab zogamicin, CMA-676) shows cytocidal effect on CD33-positive leukemia cell lines, but is inactive on P-glycoprotein-expressing sublines
-
K. Naito et al. Calicheamicin-conjugated humanized anti-CD33 monoclonal antibody (gemtuzumab zogamicin, CMA-676) shows cytocidal effect on CD33-positive leukemia cell lines, but is inactive on P-glycoprotein-expressing sublines Leukemia 14 2000 1436 1443 (Pubitemid 30601355)
-
(2000)
Leukemia
, vol.14
, Issue.8
, pp. 1436-1443
-
-
Naito, K.1
Takeshita, A.2
Shigeno, K.3
Nakamura, S.4
Fujisawa, S.5
Shinjo, K.6
Yoshida, H.7
Ohnishi, K.8
Mori, M.9
Terakawa, S.10
Ohno, R.11
-
88
-
-
0043240102
-
Multidrug resistance protein attenuates gemtuzumab ozogamicin-induced cytotoxicity in acute myeloid leukemia cells
-
DOI 10.1182/blood-2003-02-0396
-
R.B. Walter et al. Multidrug resistance protein attenuates gemtuzumab ozogamicin-induced cytotoxicity in acute myeloid leukemia cells Blood 102 2003 1466 1473 (Pubitemid 36988058)
-
(2003)
Blood
, vol.102
, Issue.4
, pp. 1466-1473
-
-
Walter, R.B.1
Raden, B.W.2
Hong, T.C.3
Flowers, D.A.4
Bernstein, I.D.5
Linenberger, M.L.6
-
89
-
-
13544266555
-
CD33-directed therapy with gemtuzumab ozogamicin in acute myeloid leukemia: Progress in understanding cytotoxicity and potential mechanisms of drug resistance
-
DOI 10.1038/sj.leu.2403598
-
M.L. Linenberger CD33-directed therapy with gemtuzumab ozogamicin in acute myeloid leukemia: progress in understanding cytotoxicity and potential mechanisms of drug resistance Leukemia 19 2005 176 182 (Pubitemid 40220577)
-
(2005)
Leukemia
, vol.19
, Issue.2
, pp. 176-182
-
-
Linenberger, M.L.1
-
90
-
-
67650733509
-
P-gP activity is a critical resistance factor against AVE9633 and DM4 cytotoxicity in leukaemia cell lines, but not a major mechanism of chemoresistance in cells from acute leukaemia patients
-
R. Tang et al. P-gP activity is a critical resistance factor against AVE9633 and DM4 cytotoxicity in leukaemia cell lines, but not a major mechanism of chemoresistance in cells from acute leukaemia patients BMC Cancer 9 2009 1 10
-
(2009)
BMC Cancer
, vol.9
, pp. 1-10
-
-
Tang, R.1
-
91
-
-
0034900174
-
Approval summary: Gemtuzumab ozogamicin in relapsed acute myeloid leukemia
-
P.F. Bross et al. Approval summary: gemtuzumab ozogamicin in relapsed acute myeloid leukemia Clin. Cancer Res. 17 2001 1490 1496 (Pubitemid 32708610)
-
(2001)
Clinical Cancer Research
, vol.7
, Issue.6
, pp. 1490-1496
-
-
Bross, P.F.1
Beitz, J.2
Chen, G.3
Xiao Hong Chen4
Duffy, E.5
Kieffer, L.6
Roy, S.7
Sridhara, R.8
Rahman, A.9
Williams, G.10
Pazdur, R.11
-
92
-
-
49449087300
-
Site-specific conjugation of a cytotoxic drug to an antibody improves the therapeutic index
-
J.R. Junutula et al. Site-specific conjugation of a cytotoxic drug to an antibody improves the therapeutic index Nat. Biotechnol. 26 2008 925 932
-
(2008)
Nat. Biotechnol.
, vol.26
, pp. 925-932
-
-
Junutula, J.R.1
-
93
-
-
84879376486
-
Conjugation site heterogeneity causes variable electrostatic properties in Fc conjugates
-
N.J. Boylan et al. Conjugation site heterogeneity causes variable electrostatic properties in Fc conjugates Bioconjug. Chem. 24 2013 1008 1016
-
(2013)
Bioconjug. Chem.
, vol.24
, pp. 1008-1016
-
-
Boylan, N.J.1
-
94
-
-
84871368732
-
Considerations for the safe and effective manufacturing of antibody drug conjugates
-
T. Rohrer Considerations for the safe and effective manufacturing of antibody drug conjugates Chem. Oggi/Chem. Today 30 2012 76 79
-
(2012)
Chem. Oggi/Chem. Today
, vol.30
, pp. 76-79
-
-
Rohrer, T.1
-
95
-
-
0025140678
-
Site-specific attachment to recombinant antibodies via introduced surface cysteine residues
-
A. Lyons et al. Site-specific attachment to recombinant antibodies via introduced surface cysteine residues Protein Eng. 3 1990 703 708 (Pubitemid 20284843)
-
(1990)
Protein Engineering
, vol.3
, Issue.8
, pp. 703-708
-
-
Lyons, A.1
King, D.J.2
Owens, R.J.3
Yarranton, G.T.4
Millican, A.5
Whittle, N.R.6
Adair, J.R.7
-
96
-
-
0034730518
-
Site-specific conjugation on serine → cysteine variant monoclonal antibodies
-
J.B. Stimmel et al. Site-specific conjugation on serine → cysteine variant monoclonal antibodies J. Biol. Chem. 39 2000 30445 30450
-
(2000)
J. Biol. Chem.
, vol.39
, pp. 30445-30450
-
-
Stimmel, J.B.1
-
97
-
-
40649126110
-
Rapid identification of reactive cysteine residues for site-specific labeling of antibody-Fabs
-
J.R. Junutula et al. Rapid identification of reactive cysteine residues for site-specific labeling of antibody-Fabs J. Immunol. Methods 332 2008 41 52
-
(2008)
J. Immunol. Methods
, vol.332
, pp. 41-52
-
-
Junutula, J.R.1
-
98
-
-
33745684533
-
Engineered antibody-drug conjugates with defined sites and stoichiometries of drug attachment
-
DOI 10.1093/protein/gzl013
-
C.F. McDonagh et al. Engineered antibody-drug conjugates with defined sites and stoichiometries of drug attachment Protein Eng. Des. Sel. 19 2006 299 307 (Pubitemid 43999640)
-
(2006)
Protein Engineering, Design and Selection
, vol.19
, Issue.7
, pp. 299-307
-
-
McDonagh, C.F.1
Turcott, E.2
Westendorf, L.3
Webster, J.B.4
Alley, S.C.5
Kim, K.6
Andreyka, J.7
Stone, I.8
Hamblett, K.J.9
Francisco, J.A.10
Carter, P.11
-
99
-
-
84867040452
-
Synthesis of site-specific antibody-drug conjugates using unnatural amino acids
-
J.Y. Axup et al. Synthesis of site-specific antibody-drug conjugates using unnatural amino acids Proc. Natl. Acad. Sci. U. S. A. 109 2012 16101 16106
-
(2012)
Proc. Natl. Acad. Sci. U. S. A.
, vol.109
, pp. 16101-16106
-
-
Axup, J.Y.1
-
100
-
-
77951236321
-
Beyond the canonical 20 amino acids: Expanding the genetic lexicon
-
T.S. Young, and P.G. Schultz Beyond the canonical 20 amino acids: expanding the genetic lexicon J. Biol. Chem. 285 2010 11039 11044
-
(2010)
J. Biol. Chem.
, vol.285
, pp. 11039-11044
-
-
Young, T.S.1
Schultz, P.G.2
-
101
-
-
84863249248
-
Aglycosylated antibodies and antibody fragments produced in a scalable in vitro transcription-translation system
-
G. Yin et al. Aglycosylated antibodies and antibody fragments produced in a scalable in vitro transcription-translation system mAbs 4 2012 217 225
-
(2012)
MAbs
, vol.4
, pp. 217-225
-
-
Yin, G.1
-
102
-
-
34249076359
-
Introducing genetically encoded aldehydes into proteins
-
DOI 10.1038/nchembio878, PII NCHEMBIO878
-
I.S. Carrico et al. Introducing genetically encoded aldehydes into proteins Nat. Chem. Biol. 3 2007 321 322 (Pubitemid 46789266)
-
(2007)
Nature Chemical Biology
, vol.3
, Issue.6
, pp. 321-322
-
-
Carrico, I.S.1
Carlson, B.L.2
Bertozzi, C.R.3
-
103
-
-
84861034877
-
Site-specific chemical protein conjugation using genetically encoded aldehyde tags
-
D. Rabuka et al. Site-specific chemical protein conjugation using genetically encoded aldehyde tags Nat. Protoc. 7 2012 1052 1067
-
(2012)
Nat. Protoc.
, vol.7
, pp. 1052-1067
-
-
Rabuka, D.1
-
104
-
-
84871947711
-
A Pictet-Spengler ligation for protein chemical modification
-
P. Agarwal et al. A Pictet-Spengler ligation for protein chemical modification Proc. Natl. Acad. Sci. U. S. A. 110 2013 46 51
-
(2013)
Proc. Natl. Acad. Sci. U. S. A.
, vol.110
, pp. 46-51
-
-
Agarwal, P.1
-
105
-
-
70349266046
-
Site specific protein labeling by enzymatic posttranslational modification
-
M. Sunbul, and J. Yin Site specific protein labeling by enzymatic posttranslational modification Org. Biomol. Chem. 7 2009 3361 3371
-
(2009)
Org. Biomol. Chem.
, vol.7
, pp. 3361-3371
-
-
Sunbul, M.1
Yin, J.2
-
106
-
-
78650297318
-
Site-specific and stiochiometric modification of antibodies by bacterial transglutaminase
-
S. Jeger et al. Site-specific and stiochiometric modification of antibodies by bacterial transglutaminase Angew. Chem. Int. Ed. 49 2010 9995 9997
-
(2010)
Angew. Chem. Int. Ed.
, vol.49
, pp. 9995-9997
-
-
Jeger, S.1
-
107
-
-
84874300889
-
Location matters: Site of conjugation modulates stability and pharmacokinetics of antibody drug conjugates
-
P. Strop et al. Location matters: site of conjugation modulates stability and pharmacokinetics of antibody drug conjugates Chem. Biol. 20 2013 161 167
-
(2013)
Chem. Biol.
, vol.20
, pp. 161-167
-
-
Strop, P.1
-
108
-
-
84859891859
-
Engineering of an anti-epidermal growth factor receptor antibody to single chain format and labeling by sortase A-mediated protein ligation
-
N.P. Madej et al. Engineering of an anti-epidermal growth factor receptor antibody to single chain format and labeling by sortase A-mediated protein ligation Biotechol. Bioeng. 109 2012 1461 1470
-
(2012)
Biotechol. Bioeng.
, vol.109
, pp. 1461-1470
-
-
Madej, N.P.1
-
109
-
-
84874343465
-
Drug-conjugated antibodies for the treatment of cancer
-
J.M. Lambert Drug-conjugated antibodies for the treatment of cancer Br. J. Clin. Pharmacol. 76 2012 248 262
-
(2012)
Br. J. Clin. Pharmacol.
, vol.76
, pp. 248-262
-
-
Lambert, J.M.1
-
110
-
-
84860121680
-
The addition of gemtuzumab ozogamicin to intensive chemotherapy in older patients with AML produces a significant improvement in overall survival: Results of the UK NCRI AML16 randomized trial
-
A.K. Burnett et al. The addition of gemtuzumab ozogamicin to intensive chemotherapy in older patients with AML produces a significant improvement in overall survival: results of the UK NCRI AML16 randomized trial Blood 118 2011 582
-
(2011)
Blood
, vol.118
, pp. 582
-
-
Burnett, A.K.1
-
111
-
-
0033052777
-
Mechanisms of action of and resistance to antitubulin agents: Microtubule dynamics, drug transport, and cell death
-
C. Dumontet, and B.I. Sikic Mechanisms of action of and resistance to antitubulin agents: microtubule dynamics, drug transport, and cell death J. Clin. Oncol. 17 1999 1061 1070 (Pubitemid 29109340)
-
(1999)
Journal of Clinical Oncology
, vol.17
, Issue.3
, pp. 1061-1070
-
-
Dumontet, C.1
Sikic, B.I.2
-
112
-
-
84864544136
-
Phase i multidose-escalation study of the anti-CD19 maytansinoid immunoconjugate SAR3419 administered by intravenous infusion every 3 weeks to patients with relapsed/refractory B-cell lymphoma
-
A. Younes et al. Phase I multidose-escalation study of the anti-CD19 maytansinoid immunoconjugate SAR3419 administered by intravenous infusion every 3 weeks to patients with relapsed/refractory B-cell lymphoma J. Clin. Oncol. 30 2012 2776 2782
-
(2012)
J. Clin. Oncol.
, vol.30
, pp. 2776-2782
-
-
Younes, A.1
-
114
-
-
79960248682
-
Phase i study of lorvotuzumab mertansine (IMGN901) in combination with lenalidomide and dexamethasone in patients with CD56-positive relapsed or relapsed/refractory multiple myeloma - A preliminary safety and efficacy analysis of the combination
-
J.G. Berdeja et al. Phase I study of lorvotuzumab mertansine (IMGN901) in combination with lenalidomide and dexamethasone in patients with CD56-positive relapsed or relapsed/refractory multiple myeloma - a preliminary safety and efficacy analysis of the combination Blood 116 2010 1934
-
(2010)
Blood
, vol.116
, pp. 1934
-
-
Berdeja, J.G.1
-
116
-
-
6044223544
-
Effects of drug loading on the antitumor activity of a monoclonal antibody drug conjugate
-
DOI 10.1158/1078-0432.CCR-04-0789
-
K.J. Hamblett et al. Effects of drug loading on the antitumor activity of a monoclonal antibody drug conjugate Clin. Cancer Res. 10 2004 7063 7070 (Pubitemid 39383058)
-
(2004)
Clinical Cancer Research
, vol.10
, Issue.20
, pp. 7063-7070
-
-
Hamblett, K.J.1
Senter, P.D.2
Chace, D.F.3
Sun, M.M.C.4
Lenox, J.5
Cerveny, C.G.6
Kissler, K.M.7
Bernhardt, S.X.8
Kopcha, A.K.9
Zabinski, R.F.10
Meyer, D.L.11
Francisco, J.A.12
-
117
-
-
84866735537
-
Pharmacokinetic considerations for antibody drug conjugates
-
K. Lin, and J. Tibbitts Pharmacokinetic considerations for antibody drug conjugates Pharm. Res. 29 2012 2354 2366
-
(2012)
Pharm. Res.
, vol.29
, pp. 2354-2366
-
-
Lin, K.1
Tibbitts, J.2
-
118
-
-
84877285215
-
Strategies to address drug interaction potential for antibody-drug conjugates in clinical development
-
D. Lu et al. Strategies to address drug interaction potential for antibody-drug conjugates in clinical development Bioanalysis 5 2013 1115 1130
-
(2013)
Bioanalysis
, vol.5
, pp. 1115-1130
-
-
Lu, D.1
-
120
-
-
84903781978
-
Multicompartmental population PK model elucidating the complex disposition of trastuzumab emtansine (T-DM1): An antibody-drug conjugate for the treatment of HER2-positive cancer [abstract]
-
B. Bender et al. Multicompartmental population PK model elucidating the complex disposition of trastuzumab emtansine (T-DM1): an antibody-drug conjugate for the treatment of HER2-positive cancer [abstract] Abstracts of the Annual Meeting Population Approach Group in Europe. Abstract nr 2607, PAGE 2012 21
-
(2012)
Abstracts of the Annual Meeting Population Approach Group in Europe. Abstract Nr 2607, PAGE
, pp. 21
-
-
Bender, B.1
-
121
-
-
84862752215
-
The effect of different linkers on target cell catabolism and pharmacokinetics/pharmacodynamics of trastuzumab maytansinoid conjugates
-
H.K. Erikson et al. The effect of different linkers on target cell catabolism and pharmacokinetics/pharmacodynamics of trastuzumab maytansinoid conjugates Mol. Cancer Ther. 11 2012 1133 1142
-
(2012)
Mol. Cancer Ther.
, vol.11
, pp. 1133-1142
-
-
Erikson, H.K.1
-
122
-
-
34548229364
-
FcRn: The neonatal Fc receptor comes of age
-
DOI 10.1038/nri2155, PII NRI2155
-
D.C. Roopenian, and S. Akilesh FcRn: the neonatal Fc receptor comes of age Nat. Rev. Immunol. 7 2007 715 725 (Pubitemid 47327396)
-
(2007)
Nature Reviews Immunology
, vol.7
, Issue.9
, pp. 715-725
-
-
Roopenian, D.C.1
Akilesh, S.2
-
123
-
-
84879591299
-
The antibody-drug conjugate: An enabling modality for natural-product based cancer therapeutics
-
H.-P. Gerber et al. The antibody-drug conjugate: an enabling modality for natural-product based cancer therapeutics Nat. Prod. Res. 2013 625 639
-
(2013)
Nat. Prod. Res.
, pp. 625-639
-
-
Gerber, H.-P.1
-
124
-
-
84874117009
-
Proposed mechanism of off-target toxicity for antibody-drug conjugates driven by mannose receptor uptake
-
B. Gorovits, and C. Krinos-Fiorotti Proposed mechanism of off-target toxicity for antibody-drug conjugates driven by mannose receptor uptake Cancer Immunol. Immunother. 62 2013 217 223
-
(2013)
Cancer Immunol. Immunother.
, vol.62
, pp. 217-223
-
-
Gorovits, B.1
Krinos-Fiorotti, C.2
-
125
-
-
49449119098
-
Antibody-drug conjugates for cancer therapy
-
P. Carter, and P. Senter Antibody-drug conjugates for cancer therapy Cancer J. 14 2008 154 168
-
(2008)
Cancer J.
, vol.14
, pp. 154-168
-
-
Carter, P.1
Senter, P.2
-
126
-
-
84863012529
-
Conjugation site modulates the in vivo stability and therapeutic activity of antibody-drug conjugates
-
B.-Q. Shen et al. Conjugation site modulates the in vivo stability and therapeutic activity of antibody-drug conjugates Nat. Biotechnol. 30 2012 184 189
-
(2012)
Nat. Biotechnol.
, vol.30
, pp. 184-189
-
-
Shen, B.-Q.1
|